Barry B. Kraus, MD; Jane W. Sinclair, PA; Donald O. Castell, MD
Study Objective: To test the potential of distance running to induce reflux in healthy subjects and the ability of ranitidine to decrease esophageal acid exposure.
Design: A randomized, single-blind, crossover study. Objective assessment of reflux was done using an ambulatory intra-esophageal pH monitor during both a baseline hour and 1 hour of running on 2 days of testing.
Subjects: Fourteen normal volunteers (10 men, four women) between 22 and 37 years of age were studied. All volunteers ran regularly, completing an average of 20 miles weekly for at least 6 months.
Interventions: Ranitidine, 300 mg orally, or an identical placebo was administered after a low-fat breakfast just before the baseline hour of pH recording.
Setting: Esophageal motility and pH probe placement was done in the gastroenterology unit at Bowman Gray Medical Center. Running was done on local jogging trails.
Measurements and Main Results: There was more gastroesophageal reflux during running than during the baseline hour when reflux was measured at a pH threshold of 3.0, 4.0, or 5.0 (P < 0.05). Reflux episodes were usually associated with belching. Ranitidine, 300 mg administered orally 1 hour before running, significantly (P < 0.05) reduced the amount of esophageal acid exposure during running.
Conclusions: Gastroesophageal reflux occurs during running in healthy volunteers. It is usually associated with belching. Acid suppression with ranitidine decreases intraesophageal acid exposure during running (P < 0.05).
Kraus BB, Sinclair JW, Castell DO. Gastroesophageal Reflux in Runners: Characteristics and Treatment. Ann Intern Med. 1990;112:429–433. doi: 10.7326/0003-4819-76-3-112-6-429
Download citation file:
Published: Ann Intern Med. 1990;112(6):429-433.
Esophageal Disorders, Gastroenterology/Hepatology, Gastroesophageal Reflux Disease, Peptic Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use